Solid Biosciences (NASDAQ:SLDB) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services [Yahoo! Finance]
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
Solid Biosciences (NASDAQ:SLDB) was upgraded by analysts at Needham & Company LLC to a "moderate buy" rating.